首页> 外文期刊>Academic Emergency Medicine >Procainamide and Survival in Ventricular Fibrillation Out-of-hospital Cardiac Arrest
【24h】

Procainamide and Survival in Ventricular Fibrillation Out-of-hospital Cardiac Arrest

机译:普鲁卡因胺与心房颤动的院外心脏骤停生存率

获取原文
获取原文并翻译 | 示例
       

摘要

Objectives: Procainamide is an antiarrhythmic drug of unproven efficacy in cardiac arrest. The association between procainamide and survival from out-of-hospital cardiac arrest was investigated to better determine the drug’s potential role in resuscitation.Methods: The authors conducted a 10-year study of all witnessed, out-of-hospital, ventricular fibrillation (VF) or pulseless ventricular tachycardia (VT) cardiac arrests treated by emergency medical services (EMS) in King County, Washington. Patients were considered eligible for procainamide if they received more than three defibrillation shocks and intravenous (IV) bolus lidocaine. Four logistic regression models were used to calculate odds ratios (ORs) and 95% confidence intervals (CI) describing the relationship between procainamide and survival.Results: Of the 665 eligible patients, 176 received procainamide, and 489 did not. On average, procainamide recipients received more shocks and pharmacologic interventions and had lengthier resuscitations. Adjusted for their clinical and resuscitation characteristics, procainamide recipients had a lower likelihood of survival to hospital discharge (OR = 0.52; 95% CI = 0.36 to 0.75). Further adjustment for receipt of other cardiac medications during resuscitation negated this apparent adverse association (OR = 1.02; 95% CI = 0.66 to 1.57).Conclusions: In this observational study of out-of-hospital VF and pulseless VT arrest, procainamide as second-line antiarrhythmic treatment was not associated with survival in models attempting to best account for confounding. The results suggest that procainamide, as administered in this investigation, does not have a large impact on outcome, but cannot eliminate the possibility of a smaller, clinically relevant effect on survival.ACADEMIC EMERGENCY MEDICINE 2010; 17:617–623 © 2010 by the Society for Academic Emergency Medicine
机译:目的:普鲁卡因酰胺是一种抗心律失常药物,在心脏骤停中的功效尚未得到证实。方法:作者对所有见证的院外室性心律失常(VF)进行了为期10年的研究,研究了普鲁卡因酰胺与院外心脏骤停生存之间的关系,以更好地确定该药在复苏中的潜在作用。 )或由华盛顿州金县的紧急医疗服务(EMS)治疗的无脉性室性心动过速(VT)心脏骤停。如果患者接受了三次以上的除颤电击和静脉(IV)利多卡因推注,则被认为符合普鲁卡因酰胺治疗的资格。四个logistic回归模型用于计算描述普鲁卡因酰胺与生存率之间关系的比值比(OR)和95%置信区间(CI)。结果:在665名合格患者中,有176例接受普鲁卡因胺治疗,而489例没有接受普鲁卡因胺治疗。平均而言,普鲁卡因胺接受者接受了更多的电击和药物干预,复苏时间更长。根据临床和复苏特征进行调整后,普鲁卡因酰胺接受者的出院生存率较低(OR = 0.52; 95%CI = 0.36至0.75)。复苏期间对其他心脏药物的接受进一步调整可以消除这种明显的不良关联(OR = 1.02; 95%CI = 0.66至1.57)。结论:在这项院外VF和无脉动性VT停止的观察性研究中,普鲁卡因胺为第二线抗心律不齐治疗与试图最好地解释混杂因素的模型的存活率无关。结果表明,在本次调查中施用的普鲁卡因酰胺不会对预后产生较大影响,但不能消除对生存率产生较小,临床相关影响的可能性。ACADEMIC EMERGENCY MEDICINE 2010; 17:617–623©2010,学术急诊医学协会

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号